

Homologous and Heterologous Covid-19 Booster Vaccin

New England Journal of Medicine

386, 1046-1057

DOI: [10.1056/nejmoa2116414](https://doi.org/10.1056/nejmoa2116414)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. Journal of Virology, 2022, 96, JVI0197321.	3.4	35
3	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. Molecular Therapy, 2022, 30, 1822-1849.	8.2	24
4	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	4.4	38
5	Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans. New England Journal of Medicine, 2022, 386, 1375-1377.	27.0	57
7	Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis. Nephrology Dialysis Transplantation, 2022, 37, 1384-1386.	0.7	7
12	SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot. Vaccines, 2022, 10, 341.	4.4	10
13	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Frontiers in Microbiology, 2022, 13, 828806.	3.5	17
16	Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients. Transplant International, 2022, 35, 10357.	1.6	10
17	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell, 2022, 185, 1572-1587.e11.	28.9	71
18	Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. Vaccines, 2022, 10, 539.	4.4	24
19	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	4.1	117
20	COVID-19 immunisation in older people. The Lancet Healthy Longevity, 2022, 3, e126-e127.	4.6	1
21	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, 2022, 185, 1549-1555.e11.	28.9	59
22	Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology, 2022, 94, 2969-2976.	5.0	191
23	COVID-19 Vaccines in Older Adults. Clinics in Geriatric Medicine, 2022, 38, 605-620.	2.6	10
27	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	10.1	27
28	Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Journal of the Formosan Medical Association, 2022, 121, 766-777.	1.7	22
29	Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody. Vaccines, 2022, 10, 556.	4.4	9

#	ARTICLE	IF	CITATIONS
32	Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COVS (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults in the VISION Network, 10 States, December 2021-March 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 495-502.	15.1	35
33	Strategies and safety considerations of booster vaccination in COVID-19. <i>Bosnian Journal of Basic Medical Sciences</i> , 2022, , .	1.0	5
34	Common Variable Immunodeficiency Associated with a De Novo IKZF1 Variant and a Low Humoral Immune Response to the SARS-CoV-2 Vaccine. <i>Journal of Clinical Medicine</i> , 2022, 11, 2303.	2.4	4
37	Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study. <i>Vaccines</i> , 2022, 10, 622.	4.4	4
38	Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers. <i>Vaccine</i> , 2022, 40, 2915-2924.	3.8	5
39	Accelerating clinical trial development in vaccinology: COVID-19 and beyond. <i>Current Opinion in Immunology</i> , 2022, 76, 102206.	5.5	4
40	Heterologous Ad.26.COVS versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination. <i>American Journal of Transplantation</i> , 2022, 22, 2254-2260.	4.7	16
41	Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clinical Infectious Diseases</i> , 2022, 75, 1980-1992.	5.8	92
43	Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 689-699.	10.7	108
45	Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety. <i>Vaccines</i> , 2022, 10, 668.	4.4	13
46	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 2088-2096.	5.8	23
47	Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study. <i>Clinics and Practice</i> , 2022, 12, 318-325.	1.4	1
48	Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. <i>Vaccines</i> , 2022, 10, 754.	4.4	10
49	Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. <i>Blood</i> , 2022, 140, 152-156.	1.4	17
50	Serial Cardiovascular Magnetic Resonance Studies Prior to and After mRNA-Based COVID-19 Booster Vaccination to Assess Booster-Associated Cardiac Effects. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 877183.	2.4	2
51	Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. <i>MedComm</i> , 2022, 3, e143.	7.2	3
53	Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2. <i>Vaccines</i> , 2022, 10, 788.	4.4	2
54	At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	11

#	ARTICLE	IF	CITATIONS
57	Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. <i>New England Journal of Medicine</i> , 2022, 386, 2433-2435.	27.0	36
58	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003953.	8.4	27
59	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022, 185, 2434-2451.e17.	28.9	289
60	Immunogenicity and Safety of Homologous and Heterologous Prime-Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 798.	4.4	20
61	Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. <i>Russian Pediatric Journal</i> , 2022, 25, 139-146.	0.2	0
62	Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. <i>Rheumatology</i> , 2022, 62, 480-485.	1.9	11
64	Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e360-e366.	5.8	21
65	Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia. <i>Vaccines</i> , 2022, 10, 838.	4.4	8
66	Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1313-1320.	9.1	58
67	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	6.0	138
68	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	21
69	A single-center COVID-19 vaccine experience with CoronaVac and BNT162b2 in familial Mediterranean fever patients. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 787-794.	1.9	4
70	Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults. <i>Journal of Clinical Virology</i> , 2022, 152, 105193.	3.1	12
71	A Case Report of MPO-ANCA-Associated Vasculitis Following Heterologous mRNA1273 COVID-19 Booster Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	14
72	Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
73	Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers—Mexico, March–December 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S167-S173.	5.8	7
74	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100679.	6.5	100
76	Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	12.8	40

#	ARTICLE	IF	CITATIONS
77	BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients. <i>Vaccines</i> , 2022, 10, 967.	4.4	12
78	Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. <i>Vaccines</i> , 2022, 10, 965.	4.4	5
79	Immunological memory to <sc>SARS-CoV-2</sc> infection and <sc>COVID-19</sc> vaccines. <i>Immunological Reviews</i> , 2022, 310, 27-46.	6.0	137
80	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). <i>Vaccine</i> , 2022, 40, 5275-5293.	3.8	3
81	Immunogenicity and Reactogenicity of Ad26.COVS in Korean Adults: A Prospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	1
84	Booster vaccination against SARS-CoV-2: current challenges and solutions. <i>Complex Issues of Cardiovascular Diseases</i> , 2022, 11, 196-203.	0.5	3
85	Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA). <i>Life</i> , 2022, 12, 966.	2.4	4
86	Risk factors and incidence rates of COVID-19 breakthrough infections in vaccinated people with vaccine booster in general medicine, Toledo (Spain), for the period December 2021 to February 2022. <i>Archives of Community Medicine and Public Health</i> , 2022, 8, 084-091.	0.2	0
87	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. <i>New England Journal of Medicine</i> , 2022, 387, 374-376.	27.0	44
88	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	14.5	84
89	Immunogenicity and efficacy of Ad26.<sc>COV2</sc>.S: An adenoviral vector-based <sc>COVID-19</sc> vaccine. <i>Immunological Reviews</i> , 2022, 310, 47-60.	6.0	10
90	Third booster vaccination and stopping the Omicron, a new variant of concern. <i>Vacunas</i> , 2022, 23, S103-S110.	2.0	5
92	Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1316-1318.	6.0	1
94	Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. <i>BMJ</i> , The, 0, , e070483.	6.0	7
95	Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 104, 115758.	1.8	7
96	Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). <i>Vaccines</i> , 2022, 10, 1064.	4.4	6
97	Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1101.	4.4	1
98	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913.	1.9	3

#	ARTICLE	IF	CITATIONS
99	Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	5
100	Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study. <i>Expert Review of Vaccines</i> , 2022, 21, 1319-1329.	4.4	12
101	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COVS vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	10
102	Animal models for COVID-19: advances, gaps and perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	40
103	Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose. <i>Vaccines</i> , 2022, 10, 1115.	4.4	10
104	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	6.0	26
105	Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 271-279.	3.1	16
106	Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine â€ A Prospective Observational Study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	13
107	Seroconversion and outcomes after initial and booster <scp>COVID</scp>â€19 vaccination in adults with hematologic malignancies. <i>Cancer</i> , 2022, 128, 3319-3329.	4.1	27
108	Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
109	A severe case of papulovesicular exanthema with rhabdomyolysis after corona virus disease 2019 heterologous booster vaccination. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	1
110	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	3.7	46
111	Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. <i>Infectious Disease Reports</i> , 2022, 14, 537-546.	3.1	23
112	Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec. <i>JAMA Network Open</i> , 2022, 5, e2223401.	5.9	1
114	Alternative Strategies to Increase the Immunogenicity of Covid-19 Vaccines in Kidney Transplant Recipients Not Responding to Two or Three Doses of an mRNA Vaccine. <i>A Randomized Clinical Trial. SSRN Electronic Journal</i> , 0, , .	0.4	4
115	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. <i>International Journal of Biological Sciences</i> , 2022, 18, 4629-4641.	6.4	24
117	COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. <i>Vaccines</i> , 2022, 10, 1223.	4.4	12
118	Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. <i>Nature Communications</i> , 2022, 13, .	12.8	6

#	ARTICLE	IF	CITATIONS
119	Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	8
120	Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. <i>Vaccines</i> , 2022, 10, 1208.	4.4	5
122	Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. <i>Gut</i> , 2023, 72, 295-305.	12.1	29
123	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	16
124	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1585-1593.	0.9	12
127	A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. <i>MBio</i> , 2022, 13, .	4.1	28
128	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. <i>JAMA Network Open</i> , 2022, 5, e2226335.	5.9	42
129	Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. <i>Trends in Molecular Medicine</i> , 2022, 28, 1082-1099.	6.7	11
130	Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. <i>Immunity</i> , 2022, 55, 1856-1871.e6.	14.3	54
131	Geographic, Occupational, and Sociodemographic Variations in Uptake of COVID-19 Booster Doses Among Fully Vaccinated US Adults, December 1, 2021, to January 10, 2022. <i>JAMA Network Open</i> , 2022, 5, e2227680.	5.9	15
133	The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	5
137	Humoral response to heterologous prime-boost vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine. <i>Transplant Infectious Disease</i> , 0, , .	1.7	1
138	The Race for Global Equitable Access to COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1306.	4.4	26
139	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	2.8	12
140	SARS-CoV-2 vaccine-induced antibody levels: what lies beneath. <i>Lancet Rheumatology</i> , The, 2022, 4, e579-e581.	3.9	0
141	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. <i>International Journal of Infectious Diseases</i> , 2022, 123, 183-191.	3.3	8
142	SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA. <i>Emerging Infectious Diseases</i> , 2022, 28, .	4.3	7
143	Clinical Characteristics of Patients Who Contracted the SARS-CoV-2 Omicron Variant from an Outbreak in a Single Hospital. <i>Yonsei Medical Journal</i> , 2022, 63, 790.	2.2	8

#	ARTICLE	IF	CITATIONS
144	High-resolution analysis of individual spike peptide-specific CD4 ⁺ T cell responses in vaccine recipients and COVID-19 patients. <i>Clinical and Translational Immunology</i> , 2022, 11, .	3.8	10
145	Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
146	Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. <i>Health Evaluation and Promotion</i> , 2022, 49, 462-469.	0.0	0
147	Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10752.	2.6	25
148	Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2438-2445.	1.7	4
149	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1703-1715.	9.1	37
150	Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. <i>PLoS Pathogens</i> , 2022, 18, e1010830.	4.7	11
151	Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
152	Covid-19 Vaccines – Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	27.0	266
153	Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. <i>Nature Communications</i> , 2022, 13, .	12.8	18
154	Durability of Protection Post-Primary COVID-19 Vaccination in the United States. <i>Vaccines</i> , 2022, 10, 1458.	4.4	8
157	Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 121-131.	1.7	9
158	Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study. <i>Vaccines</i> , 2022, 10, 1497.	4.4	7
159	Simulating the efficacy of vaccines on the epidemiological dynamics of SARS-CoV-2 in a membrane computing model. <i>MicroLife</i> , 2022, 3, .	2.1	3
160	Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries in Japan. <i>Clinical Infectious Diseases</i> , 2023, 76, 18-24.	5.8	18
161	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	1.0	4
162	Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection. <i>Med</i> , 2022, 3, 827-837.e3.	4.4	13
163	Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy. <i>International Journal of Cancer</i> , 2023, 152, 679-685.	5.1	1

#	ARTICLE	IF	CITATIONS
164	Heterologous prime boost COVID 19 vaccination. <i>Infectious Diseases Now</i> , 2022, , .	1.6	0
165	Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination. <i>Vaccines</i> , 2022, 10, 1608.	4.4	3
166	Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. <i>Oncolmmunology</i> , 2022, 11, .	4.6	10
167	Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CoV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data. <i>Vaccine</i> , 2022, 40, 6512-6519.	3.8	6
168	Four-wheel-drive immune protection. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	0
169	SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> , 2022, 55, 1779-1798.	14.3	50
170	Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. <i>BMJ, The</i> , 0, , e072141.	6.0	82
171	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. <i>Cell Reports</i> , 2022, 41, 111544.	6.4	17
172	Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines. <i>PLoS Pathogens</i> , 2022, 18, e1010885.	4.7	10
173	â€Mix and Matchâ€™ vaccination: Is dengue next?. <i>Vaccine</i> , 2022, 40, 6455-6462.	3.8	0
174	Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	15
175	Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. <i>British Journal of Cancer</i> , 2022, 127, 1827-1836.	6.4	18
176	Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CoV or BNT162b2 vaccines in Lima, Peru. <i>PLoS ONE</i> , 2022, 17, e0268419.	2.5	4
177	Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel. <i>Vaccines</i> , 2022, 10, 1797.	4.4	2
178	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	7.0	77
179	Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1677.	4.4	0
180	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. <i>IScience</i> , 2022, 25, 105465.	4.1	2
181	The Correlates & Public Health Consequences of Prospective Vaccine Hesitancy among Individuals Who Received COVID-19 Vaccine Boosters in the U.S.. <i>Vaccines</i> , 2022, 10, 1791.	4.4	5

#	ARTICLE	IF	CITATIONS
183	Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 307-319.	9.1	31
184	Effectiveness of COVID-19 Vaccination on Reduction of Hospitalizations and Deaths in Elderly Patients in Rio Grande do Norte, Brazil. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13902.	2.6	7
185	Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose. <i>Vaccines</i> , 2022, 10, 1672.	4.4	2
186	Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	2
187	Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. <i>IScience</i> , 2022, 25, 105479.	4.1	24
188	Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations. <i>Vaccines</i> , 2022, 10, 1869.	4.4	1
189	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. <i>Vaccines</i> , 2022, 10, 1924.	4.4	8
190	Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand. <i>International Journal of Infectious Diseases</i> , 2023, 126, 31-38.	3.3	18
191	Regulatory agencies disregard real-world effectiveness evidence on product labels beyond what is reasonable. <i>Journal of Clinical Epidemiology</i> , 2022, , .	5.0	0
192	Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	15
193	Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.CoV2.S in Humans Using a Mechanistic Modeling and Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 380-389.	4.7	3
194	Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 635-646.	7.0	8
195	Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
196	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. <i>Journal of Clinical Virology</i> , 2022, 157, 105328.	3.1	10
197	The Vaccine World of COVID-19: India's Contribution. <i>Vaccines</i> , 2022, 10, 1943.	4.4	7
198	Ad26.COVS priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. <i>IScience</i> , 2023, 26, 105753.	4.1	4
199	Third booster vaccination and stopping the Omicron, a new variant of concern. <i>Vacunas (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	0
200	Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia. <i>Vaccines</i> , 2022, 10, 1981.	4.4	3

#	ARTICLE	IF	CITATIONS
201	Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and Omicron predominance in Thailand: a test-negative, case-control study. , 2023, 10, 100121.		12
202	Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years. Scientific Reports, 2022, 12, .	3.3	5
203	B-cell lymphoma family proteins activated proteases as potential therapeutic targets for influenza A virus and severe acute respiratory syndrome coronavirus 2: Killing two birds with one stone?. Reviews in Medical Virology, 0, , .	8.3	0
204	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines, 2022, 10, 2035.	4.4	3
206	Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. International Journal of Molecular Sciences, 2022, 23, 14367.	4.1	4
207	Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile. Clinical Microbiology and Infection, 2023, 29, 541.e1-541.e7.	6.0	2
208	Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2. Vaccines, 2022, 10, 2146.	4.4	4
210	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
212	Impact of SARS-CoV-2 exposure history on the T cell and IgG response. Cell Reports Medicine, 2023, 4, 100898.	6.5	13
213	Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. IScience, 2023, 26, 105862.	4.1	8
214	Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. Nature Communications, 2022, 13, .	12.8	18
215	New insights in assessment of total antibodies after receiving booster dose of different COVID-19 vaccines in Serbia. , 2022, 96, 440-445.		0
216	The benefits and costs of U.S. employer COVID-19 vaccine mandates. Risk Analysis, 2023, 43, 2053-2068.	2.7	1
220	Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	8
221	Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program. Scientific Reports, 2023, 13, .	3.3	10
222	SARS-CoV-2 mRNA Dual Immunization Induces Innate Transcriptional Signatures, Establishes T-Cell Memory and Coordinates the Recall Response. Vaccines, 2023, 11, 103.	4.4	1
223	Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme. Vaccines, 2023, 11, 182.	4.4	2
224	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	4.4	14

#	ARTICLE	IF	CITATIONS
225	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	2.1	4
226	Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study. <i>Journal of Clinical Virology</i> , 2023, 159, 105374.	3.1	3
227	A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. <i>Nano Today</i> , 2023, 48, 101730.	11.9	10
228	Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 166-175.	3.3	6
229	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	8.2	12
230	The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7811-7821.	2.7	2
231	Antibody and T-Cell Responses against SARS-CoV-2 after Booster Vaccination in Patients on Dialysis: A Prospective Observational Study. <i>Vaccines</i> , 2023, 11, 260.	4.4	4
232	Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	0
233	Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	2
234	Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models. <i>Nature Communications</i> , 2023, 14, .	12.8	10
235	The immunologically high-risk kidney recipient in the early post-COVID-19 period. To do or not to do? A case report. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
236	Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 185.	2.3	0
237	SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. <i>Viruses</i> , 2023, 15, 751.	3.3	3
238	Progress in vaccine development for infectious diseasesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1524, 65-86.	3.8	3
239	Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies. , 2023, 2, 100091.		0
240	Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. <i>International Immunopharmacology</i> , 2023, 118, 109998.	3.8	1
241	Assessing parameter sensitivity in a university campus COVID-19 model with vaccinations. <i>Infectious Disease Modelling</i> , 2023, 8, 374-389.	1.9	0
242	Multicentric Observational Study on Safety and Tolerability of COVID-19 Vaccines in Patients with Angioedema with C1 Inhibitor Deficiency: Data from Italian Network on Hereditary and Acquired Angioedema (ITACA). <i>Vaccines</i> , 2023, 11, 852.	4.4	2

#	ARTICLE	IF	CITATIONS
243	Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. <i>Vaccine</i> , 2023, 41, 1925-1933.	3.8	11
244	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	20
245	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. <i>Chinese Medical Journal</i> , 2023, 136, 24-33.	2.3	2
246	Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	4
247	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. <i>Pathogens</i> , 2023, 12, 244.	2.8	8
248	Heterologous versus homologous primary and booster COVID-19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: Insights from a real-life, multicenter, case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	2.4	4
250	Effect of COVID-19 Vaccination on the In-Hospital Prognosis of Patients Admitted during Delta and Omicron Waves in Italy. <i>Vaccines</i> , 2023, 11, 373.	4.4	4
251	Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget. <i>Vaccines</i> , 2023, 11, 377.	4.4	1
252	T Cell Responses to SARS-CoV-2. <i>Annual Review of Immunology</i> , 2023, 41, 343-373.	21.8	48
253	Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study. <i>Biomedicines</i> , 2023, 11, 511.	3.2	3
254	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
255	Recent advances in respiratory immunization: A focus on COVID-19 vaccines. <i>Journal of Controlled Release</i> , 2023, 355, 655-674.	9.9	7
256	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	3.2	28
257	COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation. <i>International Cancer Conference Journal</i> , 0, , .	0.5	0
258	Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection. <i>Emerging Microbes and Infections</i> , 2023, 12, .	6.5	0
259	Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms. <i>Annals of Hematology</i> , 2023, 102, 819-827.	1.8	2
260	The Coming of Age of Nucleic Acid Vaccines during COVID-19. <i>MSystems</i> , 2023, 8, .	3.8	5
261	IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose. <i>Brazilian Journal of Microbiology</i> , 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
262	Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	8
263	Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. <i>EBioMedicine</i> , 2023, 89, 104475.	6.1	4
264	Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	5
265	Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 613-623.	10.7	14
266	Assessing acceptability of the fourth dose against COVID-19 among Chinese adults: A population-based survey. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	7
267	Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. <i>BMJ</i> , The, 0, , e072808.	6.0	17
269	Heterologous Vector mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines. <i>Vaccines</i> , 2023, 11, 701.	4.4	3
270	Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. <i>Blood Advances</i> , 0, , .	5.2	1
271	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	2.5	2
272	Korean Red Ginseng Potentially Improves Maintaining Antibodies after COVID-19 Vaccination: A 24-Week Longitudinal Study. <i>Nutrients</i> , 2023, 15, 1584.	4.1	2
273	Tracking B Cell Memory to SARS-CoV-2 Using Rare Cell Analysis System. <i>Vaccines</i> , 2023, 11, 735.	4.4	0
274	Hybrid immunity provides protective advantage over vaccination or prior remote COVID-19 alone. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	2
275	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6369.	4.1	4
278	Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 705-717.	3.1	6
279	An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses. <i>Npj Vaccines</i> , 2023, 8, .	6.0	10
280	Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2023, 77, 560-564.	5.8	7
281	Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. <i>Vaccine</i> , 2023, 41, 3497-3505.	3.8	3
282	Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0

#	ARTICLE	IF	CITATIONS
283	Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. <i>Lancet Regional Health - Europe</i> , The, 2023, 28, 100613.	5.6	6
284	COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 395-396.	10.7	2
285	ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination. <i>Case Reports in Nephrology</i> , 2023, 2023, 1-5.	0.4	1
286	Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COVS vaccine. <i>Infection</i> , 0, , .	4.7	0
287	SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	4
288	Serologic response to COVID-19 infection or vaccination in pediatric kidney transplant recipients compared to healthy children. <i>Transplant Immunology</i> , 2023, 78, 101839.	1.2	2
289	Antibody titer after administration of mRNA-based vaccine against severe acute respiratory syndrome coronavirus 2 in liver transplant recipients. <i>Annals of Gastroenterological Surgery</i> , 0, , .	2.4	2
290	Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2023, 87, 18-26.	3.3	7
291	mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
292	Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants: A population-based, matched cohort study. <i>PLoS ONE</i> , 2023, 18, e0282806.	2.5	10
293	Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK. <i>Nature Communications</i> , 2023, 14, .	12.8	10
294	A Case of de novo MPO-associated Central Nervous System Vasculitis Following Heterogeneous mRNA1273 COVID-19 Booster Vaccination. <i>Journal of the Korean Neurological Association</i> , 2023, 41, 145-148.	0.1	0
295	Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study. <i>The Lancet Healthy Longevity</i> , 2023, 4, e188-e199.	4.6	5
297	Homologous Sequential Immunization Using Salmonella Oral Administration Followed by an Intranasal Boost with Ferritin-Based Nanoparticles Enhanced the Humoral Immune Response against H1N1 Influenza Virus. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	2
298	GRAD-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. <i>Cell Reports Medicine</i> , 2023, 4, 101084.	6.5	2
299	Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses in fall 2021, Wisconsin. <i>BMC Infectious Diseases</i> , 2023, 23, .	2.9	1
300	Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost. <i>Vaccine</i> , 2023, 41, 4206-4211.	3.8	1
301	Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination. <i>Scientific Reports</i> , 2023, 13, .	3.3	4

#	ARTICLE	IF	CITATIONS
302	Herbal medicine use in Republic of Korea to alleviate side effects of COVID-19 vaccines: A cross-sectional study. <i>Journal of Integrative Medicine</i> , 2023, , .	3.1	0
303	Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study. <i>PLoS ONE</i> , 2023, 18, e0287128.	2.5	1
304	SARS-CoV-2 vaccination and immune response. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2023, 34, 363-368.	0.1	0
305	Common Adverse Events from Mixing COVID-19 Vaccine Booster in Hanoi, Vietnam. <i>Vaccines</i> , 2023, 11, 1097.	4.4	1
306	Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. <i>Vaccine</i> , 2023, 41, 4648-4657.	3.8	3
307	Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects. <i>Heliyon</i> , 2023, 9, e17410.	3.2	2
308	Management of Severe Cerebral Venous Sinus Thrombosis After Post-vaccination Breakthrough COVID-19 Infection: A Case Report and Review of the Literature. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.6	0
309	Humoral <scp>SARS</scp>â€“<scp>CoV</scp>â€“2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster. <i>Arthritis Care and Research</i> , 2024, 76, 105-110.	3.4	1
310	Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2023, 3, .	0.5	0
311	Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India. <i>Vaccine</i> , 2023, 41, 4808-4822.	3.8	1
312	Safety and immunogenicity of a third dose of mRNAâ€“1273 vaccine among cancer patients. <i>Cancer Communications</i> , 0, , .	9.2	2
314	Heterologous versus homologous boosting elicits qualitatively distinct, BA.5â€“cross-reactive T cells in transplant recipients. <i>JCI Insight</i> , 2023, 8, .	5.0	5
315	Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay. <i>Viruses</i> , 2023, 15, 1162.	3.3	1
316	Anti-SARS-CoV-2 antibody among SARS-CoV-2 vaccinated vs post-infected blood donors in a tertiary hospital, Bangkok, Thailand. <i>PLoS ONE</i> , 2023, 18, e0285737.	2.5	0
317	COVID-19 Nedeni ile Yatarak Tedavi GÃ¶renlerde AÃ¶Ã¼larÃ±n ve HatÃ¼rletme DozlarÃ±nÃ± HastalÃ±k SÃ¼recine ve Mortaliteye Etkisi. <i>Cukurova Anestezi Ve Cerrahi Bilimler Dergisi</i> , 2023, 6, 130-139.	0.0	0
318	DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond. <i>Vaccines</i> , 2023, 11, 1016.	4.4	4
319	Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands. <i>Vaccine</i> , 2023, 41, 4319-4326.	3.8	3
320	Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters. <i>Communications Medicine</i> , 2023, 3, .	4.2	1

#	ARTICLE	IF	CITATIONS
321	COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. <i>Eurosurveillance</i> , 2023, 28, .	7.0	0
322	Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: A meta-analysis. <i>Blood Advances</i> , 0, , .	5.2	0
323	Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2023, 22, 620-628.	4.4	1
325	Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies. <i>Cancer Medicine</i> , 0, , .	2.8	0
326	Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects. <i>Diagnostic Microbiology and Infectious Disease</i> , 2023, 107, 116017.	1.8	0
328	Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2023, 8, .	6.0	9
329	Breakthrough SARS-CoV-2 Omicron Variant in Individuals Primed with Heterologous Vaccines Enhances Inhibition Performance of Neutralizing Antibody to BA.2 Parental Lineage. <i>Vaccines</i> , 2023, 11, 1230.	4.4	2
330	Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination. <i>Nature Communications</i> , 2023, 14, .	12.8	2
331	Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
332	Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	2
334	CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design. <i>BMJ Open</i> , 2023, 13, e071446.	1.9	3
335	Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6–7 months of age: a phase 1/2 randomized trial. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	1
336	Immunologic response and seroconversion following third-dose COVID-19 vaccination in solid organ transplant recipients: A meta-analysis. <i>Transplant Immunology</i> , 2023, 80, 101902.	1.2	0
337	COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future. <i>Journal of Infectious Diseases</i> , 2023, 228, S55-S69.	4.0	1
338	Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. <i>Lancet Microbe, The</i> , 2023, 4, e670-e682.	7.3	4
339	Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	1
340	Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2. <i>IScience</i> , 2023, 26, 107554.	4.1	1
341	Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2023, 37, 100788.	2.9	0

#	ARTICLE	IF	CITATIONS
342	A Mechanical Assay for the Quantification of Anti-RBD IgG Levels in Finger-Prick Whole Blood. <i>ACS Sensors</i> , 2023, 8, 2986-2995.	7.8	1
344	SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
345	Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. <i>Nature Medicine</i> , 2023, 29, 2334-2346.	30.7	13
346	Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. <i>Vaccine</i> , 2023, , .	3.8	0
347	Clinical characteristics, management, and prevention of coronavirus disease 2019. <i>Frigid Zone Medicine</i> , 2023, 3, 134-160.	0.3	0
348	Effectiveness of Mix-and-Match Vaccination in Preventing SARS-CoV-2 Omicron Variant Infection in Taiwan: A Test-Negative Control Study. <i>Vaccines</i> , 2023, 11, 1441.	4.4	0
349	Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022. <i>Vaccines</i> , 2023, 11, 1461.	4.4	0
350	Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD™ and COVAXIN® induced immunity in COVID-19 exposed Indians. <i>Npj Vaccines</i> , 2023, 8, .	6.0	2
351	Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
352	Comparative Evaluation of the Clinical Severity of COVID-19 of Vaccinated and Unvaccinated Patients in Southeastern Romania in the First 6 Months of 2022, during the Omicron Wave. <i>Healthcare (Switzerland)</i> , 2023, 11, 2184.	2.0	1
353	Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
354	Comparison of Humoral Response between Third and Fourth Doses of COVID-19 Vaccine in Hemodialysis Patients. <i>Vaccines</i> , 2023, 11, 1584.	4.4	1
355	Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial. <i>EClinicalMedicine</i> , 2023, 64, 102231.	7.1	1
356	Active and Passive Immunization Approaches in Transplant Recipients. <i>Current Transplantation Reports</i> , 0, , .	2.0	0
357	Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2023, , 82-82.	0.2	0
358	Research progress on the neutralizing antibody response to SARS-CoV-2. <i>Scientia Sinica Vitae</i> , 2023, 53, 1490-1498.	0.3	0
359	Significant increase in anti-SARS-CoV-2 antibodies after administration of heterologous mRNA-based vaccine booster in individuals receiving two doses of inactivated COVID-19 vaccine: A single-center study in healthcare workers in Jakarta, Indonesia. <i>Journal of Infection and Public Health</i> , 2023, 16, 1848-1851.	4.1	0
360	Nosocomial outbreak in a respiratory ward caused by the SARS-CoV-2 Omicron BA 5.2.1 subvariant associated with non-severe illness in vaccinated patients. <i>Epidemiology and Infection</i> , 2023, 151, .	2.1	1

#	ARTICLE	IF	CITATIONS
361	Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative caseâ€“control study. <i>The Lancet Regional Health Americas</i> , 2023, 27, 100607.	2.6	3
362	Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine. <i>Heliyon</i> , 2023, 9, e20555.	3.2	6
363	Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases. <i>IJID Regions</i> , 2023, , .	1.3	0
364	Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
365	Humoral and cellular immune responses in fully vaccinated individuals with or without SARSâ€“CoVâ€“2 breakthrough infection: Results from the CoVâ€“ADAPT cohort. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	0
366	Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. <i>EClinicalMedicine</i> , 2023, 64, 102249.	7.1	0
367	IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers. <i>Medicine (United States)</i> , 2023, 102, e35444.	1.0	0
368	Immune-Boosting Effect of the COVID-19 Vaccine: Real-World Bidirectional Cohort Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e47272.	2.6	1
370	BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, , .	4.5	1
371	Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries. <i>Vaccine</i> , 2023, 41, 7007-7018.	3.8	1
372	Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 1178-1186.	3.1	1
373	Dynamics of temporal immune responses in nonhuman primates and humans immunized with COVID-19 vaccines. <i>PLoS ONE</i> , 2023, 18, e0287377.	2.5	0
374	Humoral and cellular immunity against diverse SARS-CoV-2 variants. <i>Journal of Genetics and Genomics</i> , 2023, 50, 934-947.	3.9	1
375	Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. <i>International Journal of Infectious Diseases</i> , 2023, 137, 28-39.	3.3	3
376	Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
377	Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility. <i>Nature Communications</i> , 2023, 14, .	12.8	0
378	The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18â€“59 Years and over 60 Years Based on Two Randomized Controlled Trials in China. <i>Vaccines</i> , 2023, 11, 1815.	4.4	1
379	Vaccine-induced immune thrombotic thrombocytopenia post COVID-19 booster vaccination in Brazil: a case series. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102243.	2.3	3

#	ARTICLE	IF	CITATIONS
380	Homologous Ad26.COVS vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection. <i>PLoS Pathogens</i> , 2023, 19, e1011772.	4.7	0
381	Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study “ final study results. <i>IJID Regions</i> , 2024, 10, 35-43.	1.3	0
382	Impact of Nutritional Status on Antibody Titer After Booster mRNA COVID-19 Vaccine Among Elderly Adults in Japan. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	0
383	The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	2
384	Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
386	Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants. <i>PLoS ONE</i> , 2023, 18, e0295594.	2.5	0
387	SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19. <i>Science Immunology</i> , 2023, 8, .	11.9	4
388	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	3.4	0
389	An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	1
390	Antibody response to three-dose anti-SARS-CoV-2 mRNA vaccination in treated solid cancer patients. <i>International Journal of Cancer</i> , 2024, 154, 1371-1376.	5.1	0
391	Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study. <i>Viral Immunology</i> , 2024, 37, 16-23.	1.3	0
392	Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2023, , .	9.1	5
393	Development of COVID-19 vaccine policy “ United States, 2020–2023. <i>Vaccine</i> , 2023, , .	3.8	2
396	SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0
397	Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study. <i>Vaccines</i> , 2024, 12, 83.	4.4	0
399	Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. <i>Kidney Diseases (Basel, Switzerland)</i> , 2024, 10, 107-117.	2.5	0
400	Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population. <i>Vaccines</i> , 2024, 12, 103.	4.4	2
401	Placental Transfer Efficiency of Neutralizing Antibodies on SARS-CoV-2 Vaccination before and after Pregnancy in Mexican Women. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1516.	4.1	0

#	ARTICLE	IF	CITATIONS
402	The Importance of Natural and Acquired Immunity to SARS-CoV-2 Infection in Patients on Peritoneal Dialysis. <i>Vaccines</i> , 2024, 12, 135.	4.4	0
403	Relative effectiveness and durability of booster doses of SARS-CoV-2 vaccines: A systematic review and meta-analysis. , 2024, 2, 100051.		0
406	Third vaccine boosters and antiâ€œscp>Sâ€œlg</scp> levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 0, , .	1.9	0
407	Vaccine Effectiveness against SARS-CoV-2 Infection during the Circulation of Alpha, Delta, or Omicron Variants: A Retrospective Cohort Study in a Tertiary Hospital in Serbia. <i>Vaccines</i> , 2024, 12, 211.	4.4	0
408	Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2024, 23, 266-282.	4.4	0
409	Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkinâ€™s Lymphoma: A Single-Center Cohort Study. <i>Viruses</i> , 2024, 16, 328.	3.3	0
410	Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. <i>BMC Infectious Diseases</i> , 2024, 24, .	2.9	0
411	SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. <i>Immunity</i> , 2024, 57, 587-599.e4.	14.3	0
412	The evolution of vaccine hesitancy through the COVID-19 pandemic: A semi-structured interview study on booster and bivalent doses. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0
413	Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study. <i>Vaccine</i> , 2024, 42, 2357-2369.	3.8	0
414	Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines. <i>Cureus</i> , 2024, , .	0.5	0
415	Nanotechnologyâ€™s frontier in combatting infectious and inflammatory diseases: prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	17.1	0
416	Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention. <i>Vaccines</i> , 2024, 12, 298.	4.4	0
418	Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant. <i>Expert Review of Vaccines</i> , 2024, 23, 432-444.	4.4	0